Form 4: Precigen Chief Commercial Officer Awarded 125,000 Restricted Stock Units

Phil Tennant, Precigen's Chief Commercial Officer, has been granted 125,000 Restricted Stock Units, aligning his interests with shareholder value through a multi-year vesting schedule.

Summary

• Phil Tennant, the Chief Commercial Officer of Precigen, Inc. (PGEN), reported the acquisition of 125,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was June 26, 2025.
• Each RSU represents a contingent right to receive one share of Precigen common stock.
• The RSUs will vest 50% on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years.
• Following this transaction, Mr. Tennant beneficially owns 125,000 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive signal for retention and alignment of interests, indicating confidence in the executive's role and future contributions. It's a standard compensation practice, so not highly impactful on its own, but leans positive.

Positives

• The grant of Restricted Stock Units to a key executive like the Chief Commercial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The multi-year vesting schedule encourages long-term commitment and strategic focus from the executive.

Future Outlook

The vesting schedule for the Restricted Stock Units extends over several years, indicating a long-term incentive structure for the Chief Commercial Officer, with the first significant vesting occurring in May 2026 and continuing monthly for three years thereafter.

Management Comments

• The filing indicates that Phil Tennant, Chief Commercial Officer, was granted 125,000 Restricted Stock Units.

Industry Context

The granting of Restricted Stock Units (RSUs) to key executives is a common and standard practice within the biotechnology and broader corporate sectors. It serves as a non-cash compensation method designed to align executive incentives with long-term company performance and shareholder value creation, particularly in industries with long development cycles like biotech.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice across various industries, including biotechnology, and is consistent with global benchmarks for incentivizing and retaining key personnel.
• The vesting schedule, which includes an initial cliff vesting followed by monthly installments over several years, is a common structure designed to promote long-term commitment and performance, similar to compensation plans observed at comparable biotech firms.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of 125,000 Restricted Stock Units to Phil Tennant, the Chief Commercial Officer, constitutes a related party transaction as it involves compensation provided by the company to an executive officer.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Commercial Officer's interests with shareholder value creation, potentially leading to improved long-term performance. However, it also represents potential future dilution upon vesting, though the amount is relatively small.
• Employees: This grant may serve as a positive signal regarding executive incentives and the company's commitment to performance-based compensation.

Next Steps

• The Restricted Stock Units will begin vesting, with 50% vesting on May 23, 2026.
• Subsequent vesting will occur in equal monthly installments for three years following the initial vesting date.

Key Dates

Keywords

Precigen, PGEN, Phil Tennant, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Stock Grant, Biotechnology